Food research international (Ottawa, Ont.)
Cure8 research brief
Why This Matters
The work highlights a dietary polysaccharide that reduced inflammation and improved mucosal barrier function in a mouse colitis model through gut-microbiota changes — a mechanism relevant to IBD research and potential microbiome-directed therapies.
Who Should Pay Attention
Researchers studying the microbiome, mucosal immunology, or preclinical IBD models; clinicians interested in emerging microbiome-targeted therapies; patients curious about dietary or microbiota-directed research (note: preclinical evidence only).
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
The study isolated and chemically characterized DOP-W-1, then tested it in a dextran sulfate sodium (DSS) mouse model of colitis. Treated mice had less weight loss, improved colon length and histology, better mucus barrier integrity, lower intestinal permeability, and reduced inflammatory cytokine changes.
Microbiome sequencing showed enrichment of Akkermansia and suppression of taxa linked to DSS colitis; antibiotic depletion stopped the benefit and fecal transplant from treated donors reproduced protection, supporting a microbiota-dependent mechanism.
The investigators also performed microbial functional profiling and metabolomics: DOP-W-1 appeared to restore microbial carbohydrate-active enzyme patterns linked to α-glucan use, correct aromatic amino acid–related metabolic disturbances, recover short-chain fatty acid levels, and normalize certain metabolites such as D-glucaro-1,4-lactone.
This is an abstract-level report of a mouse study (Food Research International). It suggests a microbiota-targeted polysaccharide may protect against experimental colitis, but it is preclinical and not evidence that the compound is safe or effective in humans.
Keep In Mind
This is an abstract-level summary of a preclinical (mouse) study published in a scientific journal. Results in animal models often do not translate directly to humans. The article reports mechanistic microbiome and metabolomic analyses but does not provide clinical safety or efficacy data for people with IBD.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationFood research international (Ottawa, Ont.)
AuthorsLi Z, Wang S, Wang Y +4 more
Study typeIm, journal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedJun 18, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Cimicifuga foetida L. polysaccharide alleviates ulcerative colitis by inhibiting pyroptosis and regulating gut microbiota
Researchers are exploring plant-derived polysaccharides as potential therapies that might reduce inflammation and protect the intestinal barrier. For people with UC, therapies that reduce pyroptosis and restore...
Development of double emulsions loaded with Malus baccata (Linn.) polyphenols and their protective effect on dextran sulfate sodium-induced ulcerative colitis in mice.
Researchers are exploring plant polyphenols and new oral delivery systems that might reduce gut inflammation and modify microbiota — findings in mice suggest potential but are not directly applicable to patients yet.
Mechanism and Active ingredients of Gancao Qinlian Granules in ameliorating ulcerative colitis:integrated in vivo, in vitro, network pharmacology and untargeted metabolomics investigation.
The paper presents integrated preclinical evidence that a multi-herb formula (GQG) can reduce inflammation and alter gut microbiota and metabolites in a mouse model of ulcerative colitis, highlighting possible mechanisms...